Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading live biotherapeutics company, today announced that it will host a webcast to discuss top-line results from an investigator-sponsored trial (IST) ...

For many people diagnosed with cancer, treatment with immune checkpoint inhibitors (ICIs) has dramatically extended lives. Some of these treatments, such as Keytruda and Opdivo, have become familiar ...

Recent Publication and Growing Industry Focus on Immune-Priming Strategies Support Continued Evaluation of Gedeptin(R) as a ...

Insilico Medicine has developed a new class of small molecule inhibitors targeting diacylglycerol kinase alpha (DGKα) designed to restore T cell function and overcome resistance to immune checkpoint ...

Sportschosun Jang Jong-ho] A study has found that sarcopenia may be an important indicator for predicting the prognosis of immune checkpoint inhibitor treatment ...

Therapeutic strategies which target immune checkpoint markers and enable the immune system to initiate immune responses against tumor cells represent a major advancement in cancer therapy. The ...

Once issued, this patent is expected to expire no earlier than September 2042. The allowed claims cover not only the combination of ibudilast with multiple anti-PD-1 antibodies, but also a broad range ...

Please provide your email address to receive an email when new articles are posted on . More than 50% of adenomas developed within 7.5 months of immune checkpoint inhibitor-mediated diarrhea and ...

Immune checkpoint molecules play a crucial role in keeping the immune system in balance and preventing an attack on the body's own cells. Cancer cells can use these checkpoints to hide from the immune ...

Immune checkpoint inhibitors (ICIs) are a transformative therapy for many cancers, including head and neck cancer (HNC). However, their unique mechanism can trigger immune-related adverse events. Rare ...

A new study has uncovered a key mechanism that helps one of the deadliest brain cancers evade the immune system, according to ...